Immunohistochemical analysis of prognostic protein markers for primary localized clear cell renal cell carcinoma

Cancer Investigation

Volumn 31, Issue 1, 2013, Pages 51-59

  Weber, Thomas ^a,b   Meinhardt, Matthias ^a   Zastrow, Stefan ^a   Wienke, Andreas ^b   Fuessel, Susanne ^a   Wirth, Manfred P ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Clear cell renal cell carcinoma; Ki67; Localized; P21; Prognosis; Survivin

Indexed keywords

KI 67 ANTIGEN; PROTEIN; PROTEIN P21; PROTEIN P53; SURVIVIN; TUMOR MARKER; VON HIPPEL LINDAU PROTEIN; BIRC5 PROTEIN, HUMAN; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; INHIBITOR OF APOPTOSIS PROTEIN; VHL PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; PREDICTIVE VALUE; PRIORITY JOURNAL; RECURRENCE RISK; RISK ASSESSMENT; TISSUE MICROARRAY; KIDNEY TUMOR; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TUMOR RECURRENCE; VASCULARIZATION;

AGED; CARCINOMA, RENAL CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; KI-67 ANTIGEN; KIDNEY NEOPLASMS; MALE; MICROVESSELS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

MLCS; MLOWN;

EID: 84872689960     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2012.749267     Document Type: Article

References (37)

1. Moch H, Artibani W, Delahunt B, Ficarra V, Knuechel R Montorsi F, Patard JJ, Stief CG, Sulser T,Wild PJ. Reassessing the current UICC/AJCC TNM staging for renal cell carcinoma. Eur Urol 2009;56:636-643
2. Kim HL, Seligson D, Liu X, Janzen N, Bui MH, Yu H, Shi T Figlin RA, Horvath S, Belldegrun AS. Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res 2004;10:5464-5471 (Pubitemid 39100484)
3. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003;30:843-852 (Pubitemid 37485197)
4. Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA Merseburger AS, Patard JJ, Mulders PF, Sinescu IC. EAU guidelines on renal cell carcinoma: The 2010 update. Eur Urol 2010;58:398-406
5. Suzuki K, Nishiyama T, Hara N, Akazawa K, Takahashi K. Kattan postoperative nomogram for renal cell carcinoma: Predictive accuracy in a Japanese population. Int J Urol 2011;18:194-199
6. Dahinden C, Ingold B, Wild P, Boysen G, Luu VD, Montani M KristiansenG, Sulser T, Buhlmann P,MochH, Schraml P.Mining tissue microarray data to uncover combinations of biomarker expression patterns that improve intermediate staging and grading of clear cell renal cell cancer. Clin Cancer Res 2010;16:88-98
7. Parker AS, Leibovich BC, Lohse CM, Sheinin Y, Kuntz SM, Eckel- Passow JE, Blute ML, Kwon ED. Development and evaluation of BioScore: A biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer 2009;115:2092-2103
8. Nickerson ML, Jaeger E, Shi Y, Durocher JA,Mahurkar S, Zaridze D, Matveev V, Janout V, Kollarova H, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, Mukeria A, Holcatova I Schmidt LS, Toro JR, Karami S,Hung R,GerardGF, LinehanWM Merino M, Zbar B, Boffetta P, Brennan P, RothmanN, ChowWH Waldman FM, Moore LE. Improved identification of von Hippel- Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 2008;14:4726-4734
9. Linehan WM, Rubin JS, Bottaro DP. VHL loss of function and its impact on oncogenic signaling networks in clear cell renal cell carcinoma. Int J Biochem Cell Biol 2008;41(4):753-756
10. Di Cristofano C, Minervini A, Menicagli M, Salinitri G, Bertacca G, Pefanis G, Masieri L, Lessi F, Collecchi P, Minervini R Carini M, Bevilacqua G, Cavazzana A. Nuclear expression of hypoxia-inducible factor-1alpha in clear cell renal cell carcinoma is involved in tumor progression. Am J Surg Pathol 2007;31:1875-1881 (Pubitemid 350175815)
11. Patard JJ, Rioux-Leclercq N, Masson D, Zerrouki S, Jouan F Collet N, Dubourg C, Lobel B, Denis M, Fergelot P. Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma. Br J Cancer 2009;101:1417-1424
12. Sandlund J, Hedberg Y, Bergh A, Grankvist K, Ljungberg B Rasmuson T. Evaluation of CD31 (PECAM-1) expression using tissue microarray in patients with renal cell carcinoma. Tumour Biol 2007;28:158-164 (Pubitemid 46976002)
13. Roe JS, Kim H, Lee SM, Kim ST, Cho EJ, Youn HD. p53 stabilization and transactivation by a vonHippel-Lindau protein.Mol Cell 2006;22:395-405
14. Noon AP,Vlatkovic N, Polanski R,MaguireM, ShawkiH, Parsons K, Boyd MT. p53 and MDM2 in renal cell carcinoma: Biomarkers for disease progression and future therapeutic targets? Cancer 2010;116:780-790
15. Weiss RH, Borowsky AD, Seligson D, Lin PY, Dillard-Telm L BelldegrunAS, Figlin RA, PantuckAD. p21 is a prognostic marker for renal cell carcinoma: Implications for novel therapeutic approaches. J Urol 2007;177:63-68; discussion 68-69
16. Kosari F, Parker AS, Kube DM, Lohse CM, Leibovich BC, Blute ML, Cheville JC,VasmatzisG. Clear cell renal cell carcinoma: Gene expression analyses identify a potential signature for tumor aggressiveness. Clin Cancer Res 2005;11:5128-5139 (Pubitemid 41003697)
17. Parker AS, Kosari F, Lohse CM, Houston Thompson R, Kwon ED, Murphy L, Riehle DL, Blute ML, Leibovich BC, Vasmatzis G Cheville JC. High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma. Cancer 2006;107:37-45 (Pubitemid 43939028)
18. Byun SS, Yeo WG, Lee SE, Lee E. Expression of survivin in renal cell carcinomas: Association with pathologic features and clinical outcome. Urology 2007;69:34-37 (Pubitemid 46161689)
19. Bui MH, Visapaa H, Seligson D, Kim H, Han KR, Huang Y Horvath S, Stanbridge EJ, Palotie A, Figlin RA, Belldegrun AS. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol 2004;171:2461-2466 (Pubitemid 38625515)
20. Arai E, Kanai Y. Genetic and epigenetic alterations during renal carcinogenesis. Int J Clin Exp Pathol 2011;4:58-73
21. Sobin L, Gospodarowicz M, Wittekind C. TNM Classification of Malignant Tumours. UICC International Union Against Cancer. 7th edition, New York:Wiley-Blackwell, 2009
22. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8
23. Jamieson NB, Carter CR, McKay CJ, Oien KA. Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. Clin Cancer Res 2011;17:3316-3331
24. ChoueiriM, TannirN, Jonasch E. Adjuvant and neoadjuvant therapy in renal cell carcinoma. Curr Clin Pharmacol 2011;6:144-150
25. Kroeze SG, Bijenhof AM, Bosch JL, Jans JJ. Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma. Cancer Biomark 2010;7:261-268
26. Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O'Reilly T, Natt F, Hall J, Lane HA, Thomas G. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005;120:747-759 (Pubitemid 40568794)
27. Mahotka C, Krieg T, Krieg A, Wenzel M, Suschek CV, Heydthausen M, Gabbert HE, Gerharz CD. Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int J Cancer 2002;100:30-36 (Pubitemid 34602061)
28. Klatte T, Seligson DB, LaRochelle J, Shuch B, Said JW, Riggs SB, Zomorodian N, Kabbinavar FF, Pantuck AJ, Belldegrun AS. Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Cancer Epidemiol Biomarkers Prev 2009;18:894-900
29. Shvarts O, Seligson D, Lam J, Shi T, Horvath S, Figlin R Belldegrun A, Pantuck AJ. p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma. J Urol 2005;173: 725-728 (Pubitemid 40239328)
30. Kramer BA, Gao X, Davis M, Hall M, Holzbeierlein J, Tawfik O. Prognostic significance of ploidy, MIB-1 proliferation marker and p53 in renal cell carcinoma. J Am Coll Surg 2005;201: 565-570 (Pubitemid 41393078)
31. Zlobec I, Terracciano L, Jass JR, LugliA.Value of staining intensity in the interpretation of immunohistochemistry for tumormarkers in colorectal cancer. Virchows Arch 2007;451:763-769 (Pubitemid 47497938)
32. Clark TG, BradburnMJ, Love SB, Altman DG. Survival analysis part IV: Further concepts and methods in survival analysis. Br J Cancer 2003;89:781-786 (Pubitemid 37175795)
33. Axelrod DE, Miller N, Chapman JA. Avoiding Pitfalls in the statistical analysis of heterogeneous tumors. Biomed InformInsights 2009;2:11-18
34. Lee LS, TanMH. Predictive models for the practical management of renal cell carcinoma. Nat Rev Urol 2012;9:73-84
35. Girgis AH, Iakovlev VV, Beheshti B, Bayani J, Squire JA, Bui A, Mankaruos M, Youssef Y, Khalil B, Khella HW, Pasic M Yousef GM. Multilevel whole-genome analysis reveals candidate biomarkers in clear cell renal cell carcinoma. Cancer Res 2012;72(20):5273-5284
36. Milanes-Yearsley M, Hammond ME, Pajak TF, Cooper JS, Chang C, Griffin T, Nelson D, Laramore G, Pilepich M. Tissue microarray: A cost and time-effective method for correlative studies by regional and national cancer study groups. Mod Pathol 2002;15:1366-1373 (Pubitemid 35463006)
37. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF. American Society of Clinical Oncology/ College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145 (Pubitemid 350003059)